Flash Finance

Mangalam Drugs And Organics LimitedMANGALAMCorporate

Pharmaceuticals - Indian - Bulk Drugs & Formln Latest results: Mar 2026 10 quarters of data
Consolidated Standalone
₹31.11
MCap ₹49 Cr
Mangalam Drugs And Organics Limited — Stock analysis & AI research Mangalam Drugs And Organics Limited — Seasonality — best & worst months Mangalam Drugs And Organics Limited — Technical setup — score, trend, support & resistance Mangalam Drugs And Organics Limited — Live exchange announcements
🏭 Pharma sector
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹67 Cr
Sales · Mar 2026
-8.2% YoY
₹-6 Cr
Operating Profit · Mar 2026
-160.0% YoY
-9.0%
OPM % · Mar 2026
-165.7% YoY
₹-13 Cr
Net Profit · Mar 2026
₹-8.48
EPS · Mar 2026
-21300.0% YoY

📝 Mangalam Drugs And Organics Limited — results explained

Quarter ended March 2026 (Q4 FY26)

Mangalam Drugs And Organics Limited reported revenue of ₹67 crore for the quarter ended March 2026 (Q4 FY26), down 8.2% from ₹73 crore in the same quarter last year, and up 15.5% sequentially over the December 2025 quarter.

The company reported a net loss of ₹13 crore, against a net profit of ₹0 crore in the same quarter last year. Earnings per share (EPS) came in at ₹-8.48.

Operating profit stood at ₹-6 crore — an operating margin (OPM) of -9.0%, compared with 13.7% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, Mangalam Drugs And Organics Limited posted revenue of ₹232 crore, a decline of 27.3% over FY25, with a net loss of ₹44 crore.

On a trailing-twelve-month (TTM) basis, revenue stands at ₹232 crore with a net loss of ₹44 crore.

Valuation snapshot

At the current price of ₹31.11, MANGALAM has a market capitalisation of ₹49 crore.

Within the Pharmaceuticals - Indian - Bulk Drugs & Formln industry, it is the 25th-largest of the 47 companies we track by market value.

Shareholding pattern

As of Sep 2026, promoters held 35.65%, foreign institutional investors (FIIs) 0.11%, public shareholders 64.24% of Mangalam Drugs And Organics Limited.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
₹49 Cr
Current Price ?
₹31.1
P/E ?
N/A
Industry P/E ?
37.20
P/B ?
0.48
P/S ?
0.21
P/FCF ?
-6.16
Enterprise Value ?
₹154 Cr
EV/EBITDA ?
-10.28
PEG ?
N/A
Earnings Yield ?
-21.4%
Dividend Yield ?
0.00%
Profitability & Returns
Sales (TTM) ?
₹232 Cr
OPM ?
-6.5%
Profit after tax (TTM) ?
₹-44 Cr
EPS (TTM) ?
₹-27.80
ROCE ?
-14.0%
ROE ?
-42.7%
ROA ?
-14.0%
Growth
Sales — latest qtr ?
₹67 Cr
PAT — latest qtr ?
₹-13 Cr
YoY qtr sales growth ?
-8.2%
YoY qtr profit growth ?
N/A
Sales growth (3y) ?
N/A
Sales growth (5y) ?
N/A
Profit growth (3y) ?
N/A
Profit growth (5y) ?
N/A
Financial Health
Debt ?
₹105 Cr
Debt to Equity ?
1.02
Interest Coverage ?
-2.1
Current Ratio ?
N/A
Ownership
Promoter holding ?
35.65%
Change in promoter holding ?
-14.65%
Pledged percentage ?
N/A
Market
Return 3 months ?
12.8%
Return 6 months ?
4.1%

🗓️ Quarterly results (10 quarters · ₹ Cr)

same fiscal quarter as Mar bestweakest per row · for costs (interest, NPAs) low is best
Metric Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026 YoY % QoQ %
Sales 971027780897357505867 -8.2% +15.5%
Operating Profit 71289910-4-3-2-6 -160.0% -200.0%
Other Income 0000000000 — —
Interest 3444344543 -25.0% -25.0%
Depreciation 4444454545 +0.0% +25.0%
Profit Before Tax 041112-13-12-10-13 -750.0% -30.0%
Net Profit 043310-14-7-10-13 — -30.0%
EPS 0.322.231.691.700.820.04-8.72-4.64-6.22-8.48 -21300.0% -36.3%
OPM % 7.2% 11.8% 10.4% 11.2% 10.1% 13.7% -7.0% -6.0% -3.4% -9.0% -165.7% -164.7%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric FY25 FY26 TTM YoY %
Sales ₹319 Cr ₹232 Cr ₹232 Cr -27.3%
Operating Profit ₹36 Cr ₹-15 Cr ₹-15 Cr -141.7%
OPM % 11.29% -6.47% -6.47% -157.3%
NPM % 2.19% -18.97% -18.97% -966.2%
Other Income ₹0 Cr ₹0 Cr ₹0 Cr —
Depreciation ₹17 Cr ₹18 Cr ₹18 Cr +5.9%
Interest ₹15 Cr ₹16 Cr ₹16 Cr +6.7%
EBIT ₹19 Cr ₹-33 Cr ₹-33 Cr -273.7%
PBT ₹5 Cr ₹-48 Cr ₹-48 Cr -1060.0%
Tax — — — —
Net Profit ₹7 Cr ₹-44 Cr ₹-44 Cr -728.6%
EPS ₹4.25 ₹-28.06 ₹-28.06 -760.2%
Material Cost — — — —
Employee Cost — — — —
Extraordinary Items — — — —

🏛️ Balance Sheet (latest 3 periods)

Metric Mar 2024Mar 2025Mar 2026 % Chg
Equity Capital 161616 +0.0%
Reserves 12013387 -34.6%
Borrowings 10796105 +9.4%
Other Liabilities 91121106 -12.4%
Total Liabilities 334366315 -13.9%
Fixed Assets 148163159 -2.5%
CWIP 830 -100.0%
Investments 000 —
Other Assets 178201156 -22.4%
Total Assets 334366315 -13.9%

💧 Cash Flow (latest 3 periods)

Metric Mar 2024Mar 2025Mar 2026 % Chg
Cash from Operating Activity 4434 -90.7%
Cash from Investing Activity -12-19-12 +36.8%
Cash from Financing Activity 5-226 +127.3%
Net Cash Flow -31-2 -300.0%
Free Cash Flow -823-8 -134.8%
CFO/OP 23%118%-30% -125.4%

➗ Ratios (latest 3 periods)

Metric Mar 2024Mar 2025Mar 2026 % Chg
Debtor Days 284563 +40.0%
Inventory Days 185303239 -21.1%
Days Payable 99199177 -11.1%
Cash Conversion Cycle 113149126 -15.4%
Working Capital Days 115-65 -1400.0%
ROCE % —8%-14% -275.0%

👥 Shareholding (latest 5 periods)

Metric Jun 2025Sep 2025Dec 2025Mar 2026Sep 2026 % Chg
Promoters 50.30%50.30%35.64%35.65%35.65% +0.0%
FIIs 0.53%0.11%0.13%0.32%0.11% -65.6%
Public 49.16%49.57%64.22%64.03%64.24% +0.3%
No. of Shareholders 19,72819,88121,22725,14023,991 -4.6%

⚖️ Peer comparison

Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln · top 25 of 47 companies · full page →
# Company CMP MCap (Cr) P/E Sales TTM NP TTM OPM% NPM% Sales YoY% NP YoY% Qtr Rev Δ% Qtr NP Δ%
1 AKUMS Akums Drugs ₹784.55 12,012 41.2 4,502 293 12.6% 6.5% 5.9% -25.5% 13.9% 56.1%
2 STAR Strides Pharma ₹1,085.00 10,001 26.7 3,636 389 25.4% 10.7% -20.4% 99.0% 11.2% 50.0%
3 BLUEJET Blue Jet ₹565.05 9,802 36.9 884 265 36.3% 30.0% 8.0% 0.7% -17.5% -14.3%
4 AARTIPHARM Aarti Pharmalabs ₹828.30 7,511 36.1 1,957 208 22.0% 10.6% 1.5% -26.9% 42.4% 39.2%
5 SUPRIYA Supriya Lifescience ₹870.30 7,004 35.3 873 198 33.2% 22.7% 18.9% 11.1% 30.8% -30.9%
6 INNOVACAP Innova Captab ₹1,199.30 6,863 13.8 5,779 497 14.6% 8.6% 355.1% 277.4% 33.9% 42.3%
7 MOREPENLAB Morepen Laboratories ₹123.35 6,759 48.0 1,951 141 9.4% 7.2% -0.3% -18.3% 34.1% 394.0%
8 IOLCP IOL Chemicals ₹201.19 5,905 35.2 2,523 168 12.3% 6.7% 11.5% 36.6% 37.1% 89.8%
9 FDC FDC ₹350.20 5,702 19.5 2,191 291 15.3% 13.3% 3.0% 4.8% 3.0% 9.5%
10 NOVARTIND Novartis India ₹2,257.80 5,575 57.0 371 97 27.6% 26.2% -0.3% -6.9% 18.2% 14.3%
11 ORCHPHARMA Orchid Pharma ₹1,058.75 5,370 236.9 812 22 5.1% 2.7% -11.9% -76.4% 0.2% 25.4%
12 RPGLIFE RPG Life ₹2,865.90 4,740 39.7 735 120 21.1% 16.3% 8.4% -36.9% 15.8% 16.3%
13 ZOTA Zota Health ₹1,232.70 4,269 — 609 -104 0.6% -17.1% 84.6% -29.8% 66.9% -213.9%
14 GUFICBIO Gufic Biosciences ₹419.85 4,210 57.3 974 74 16.9% 7.6% 14.7% -9.1% 14.9% 86.0%
15 UNICHEMLAB Unichem Laboratories ₹526.70 3,708 12.2 2,308 305 9.9% 13.2% 6.2% 74.1% 20.1% 496.1%
16 INDSWFTLAB Ind-Swift Laboratories ₹374.00 3,252 55.4 665 57 9.0% 8.6% 235.3% 10.1% 32.3% -88.7%
17 ADVENZYMES Advanced Enzyme ₹293.25 3,249 19.8 750 172 29.8% 22.9% 17.1% 29.6% 2.1% -4.6%
18 SOLARA Solara Active ₹667.00 3,218 85.6 1,535 37 15.2% 2.4% 6.6% -1470.4% 33.1% 381.8%
19 DCAL Dishman Carbogen ₹162.08 2,541 157.6 2,902 16 16.7% 0.6% 8.1% 2655.7% -4.3% -351.7%
20 INDOCO Indoco Remedies ₹254.59 2,347 n/m 1,872 3 8.8% 0.2% 10.7% -26.5% 6.5% 280.0%
21 PANACEABIO Panacea Biotec ₹368.55 2,257 — 673 -9 0.3% -1.3% 14.4% 17.9% 19.7% -44.4%
22 REMUS Remus Pharma. ₹1,911.30 2,252 91.1 94 25 31.7% 26.7% — — 13.3% 21.4%
23 SAKAR Sakar Healthcare ₹987.40 2,167 61.0 272 36 28.5% 13.3% 41.9% 71.8% 38.4% 120.2%
24 JAGSNPHARM Jagsonpal Pharmaceuticals ₹227.53 1,501 33.3 294 45 20.7% 15.4% 6.9% -22.2% 8.5% 20.4%
25 MANGALAM Mangalam Drugs ₹34.01 54 — 232 -44 -6.5% -19.0% -27.3% -728.6% -8.2% —
❓ Frequently asked questions
What was Mangalam Drugs And Organics Limited's revenue in Q4 FY26?
Mangalam Drugs And Organics Limited reported revenue of ₹67 crore for the quarter ended March 2026 (Q4 FY26), down 8.2% from ₹73 crore in the same quarter last year, and up 15.5% sequentially over the December 2025 quarter.
What was Mangalam Drugs And Organics Limited's net profit in Q4 FY26?
The company reported a net loss of ₹13 crore, against a net profit of ₹0 crore in the same quarter last year. Earnings per share (EPS) came in at ₹-8.48.
What is MANGALAM's market capitalisation and P/E ratio?
At the current price of ₹31.11, MANGALAM has a market capitalisation of ₹49 crore.
Who owns Mangalam Drugs And Organics Limited? (shareholding pattern)
As of Sep 2026, promoters held 35.65%, foreign institutional investors (FIIs) 0.11%, public shareholders 64.24% of Mangalam Drugs And Organics Limited.
TTM ends 2026-03-31. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price refreshed about twice a day from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI